NCT05895370 (GI-HPVT-01) is a Phase 1 clinical trial of HPV-T in Solid Tumor, sponsored by BGI, China.

Who is sponsoring NCT05895370?

NCT05895370 is sponsored by BGI, China.

What drugs are being tested in NCT05895370?

Interventions in NCT05895370: HPV-T, Interleukin-2.

What condition does NCT05895370 study?

NCT05895370 studies Solid Tumor.

Is NCT05895370 still recruiting?

NCT05895370 is currently status unknown. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT05895370: GI-HPVT-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors

Status unknown Phase 1 Last updated 8 June 2023

What this trial tests

Phase 1 trial testing HPV-T in Solid Tumor in 12 participants. Status unknown.

Timeline

13 April 2023

Primary endpoint
13 December 2024

13 April 2025

Quick facts

Lead sponsor	BGI, China
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	13 April 2023
Primary completion	13 December 2024
Estimated completion	13 April 2025
Sites	1 location across China

Drugs / interventions tested

HPV-T — full drug profile →
Interleukin-2

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

BGI, China — full company profile →

Who can join

Adults 18 to 75, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this protocol is to evaluate the feasibility and safety of HPV-T in HPV 16 positive recurrent or metastatic solid tumor patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other BGI, China trials

Trials by the same sponsor.

NCT06499025 — Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) · EARLY_PHASE1 · enrolling by invitation
NCT06224049 — Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T · EARLY_PHASE1 · recruiting
NCT02959905 — Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05895370 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BGI, China
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing